期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌EGFR基因突变以及靶向药物耐药机制的研究进展 被引量：2

Research Progress of EGFR Mutations in Lung Cancer and Targeted Drug Resistance Mechanisms
下载PDF
导出
摘要 EGFR基因突变与肺癌发生发展密切相关,介绍不同EGFR基因突变类型对靶向药物TKI的敏感性以及回顾靶向药物耐药机制的研究进展,进一步指导临床靶向用药. EGFR mutations are closely associated with lung cancer development,this paper introduces the effectiveness of tyrosine kinase inhibitors on different epidermal growth factor receptor mutations and reviews the research progress of targeted drug resistance mechanisms,the aimis to further guide clinical targeted drugs.
作者 钱璐 边莉 QIAN Lu;BIAN Li(Dept.of Pathology,The 1st Affliated Hospital of Kunming Medical University,Kunming Yunnan 650032,China)
机构地区 昆明医科大学第一附属医院病理科
出处 《昆明医科大学学报》 CAS 2017年第8期126-129,共4页 Journal of Kunming Medical University
基金 国家自然科学基金资助项目(81460355)
关键词 表皮生长因子受体 非小细胞肺癌 酪氨酸激酶抑制剂 Epidermal growth factor receptor Non-small cell lung cancer Tyrosine kinase inhibitors
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献28

  • 1Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol,2002,3(11) : 672-683.
  • 2Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol, 2001,61 ( 3 ): 253-270.
  • 3Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21(12): 2237-2246.
  • 4Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitahine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial -INTACT 1. J Clin Oncol. 2004 Mar 1;22(5): 777-784.
  • 5Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 2. J Clin Oncol,2004,22(5):785-794.
  • 6Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase Ⅲ clinical trials. Semin Oncol,2001,28(6): 620-625.
  • 7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
  • 8Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE 522, and conventional anticancer agents. Clin Cancer Res, 2002,8 (7) : 24
  • 9Crul M, de Klerk GJ, Swart M, et al. Phase Ⅰ clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol,2002,20(11): 2726-2735.
  • 10Baselga J, Rischin D, Ranson M, et al. Phase Ⅰ safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol, 2002

共引文献72

同被引文献9

引证文献2

二级引证文献4

昆明医科大学学报
2017年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部